Potent, Selective, and Orally Bioavailable Quinazoline-Based STK17A/B Dual Inhibitors-Reference-Cited by-同舟云学术

Potent, Selective, and Orally Bioavailable Quinazoline-Based STK17A/B Dual Inhibitors

Published:2024-05-20 Issue:6 Volume:15 Page:945-949
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Chaudhry Sana¹,Castro Jesus R.¹,Totiger Tulasigeri M.¹,Afaghani Jumana¹,Khurshid Rabia²,Nicholls Miah¹,Zhang Ziming³,Schürer Stephan C.¹²^ORCID,Shah Ashish¹,Taylor Justin¹,Feng Yangbo¹²^ORCID

Affiliation:

1. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida33136, United States

2. Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida 33136, United States

3. Department of Chemistry, University of Miami, Miami, Florida 33146, United State

Funder

Coulter Center for Translational Research, University of Virginia

Edward P. Evans Foundation

Doris Duke Charitable Foundation

Sylvester Comprehensive Cancer Center, University of Miami Health Systems

National Institutes of Health

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.4c00125

Reference16 articles.

1. Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration

2. Abstract LB-023: STK17A, a novel serine threonine kinase, promotes cancer stemness phenotypes by phosphorylating β-catenin

3. Serine/Threonine Kinase 17A Is a Novel Candidate for Therapeutic Targeting in Glioblastoma

4. Serine/Threonine Kinase 17A Is a Novel p53 Target Gene and Modulator of Cisplatin Toxicity and Reactive Oxygen Species in Testicular Cancer Cells

5. Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling